A clinical trial for the efficacy and safety of new Chinese herbal compound in reducing uric acid in patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000003495

Enrollment

Unknown

Registered

2020-07-17

Start date

2020-08-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Interventions

High uric acid group:new Chinese herbal compound

High uric acid and gout group:new Chinese herbal compound

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Male and female aged 18 to 65 years; patients with a diagnosis of HUA [sUA levels >=420 umol/L (7 mg/dL)in male and 360 umol/L in female]; Patients with gout and high uric acid.

Exclusion criteria

Exclusion criteria: Patients were excluded with HIV positive, hepatitis B or C infection, pregnant or lactating women, and active infection.

Design outcomes

Primary

Measure	Time frame
serum uric acid level;	—

Secondary

Measure	Time frame
blood routine examination;hepatic and renal function;	—

Countries

china

Contacts

Public ContactYao Yuanyong

Tongren University

yyy0326.love@163.com+86 15185849731

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026